Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Suzhou Basecare Medical Corporation Limited (2170.HK)
Suzhou, CN
Suzhou Basecare Medical Corporation Limited, an investment holding company established in Suzhou, China, in 2010, focuses its business activities within the People's Republic of China. The company primarily engages in the research, development, and manufacturing of genetic testing solutions specifically for assisted reproduction, alongside the distribution of related medical devices and instruments. Its extensive product line includes a range of genetic test kits for reproductive health. These comprise pre-implantation genetic tests such as PGT-A, designed to screen for chromosomal aneuploidies; PGT-M, which identifies single-gene or monogenic defects in pre-implantation embryos; and PGT-SR kits, used to detect chromosomal structural rearrangements often linked to recurrent miscarriages. Additionally, Basecare offers prenatal test kits (CNV kits) and postnatal test kits (WES kits). Complementing its genetic testing offerings, the company supplies various specialized medical equipment, including liquid nitrogen storage dewars, cryostorage systems, automated workstations, sperm quality analyzers, and next-generation sequencing (NGS) sequencers. Beyond manufacturing and sales, Basecare also provides marketing services and develops software for its medical devices and instruments. Its primary clientele consists of hospitals and reproductive clinics.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.08% | -9.03% | -26.94% | -24.60% | -34.42% | -24.19% | -50.87% | -56.62% | -95.00% | -94.91% | -94.91% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-09 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-22.0% Q4'25: -24.3% (vs Q4'24)
-
EPS growth Medical - Devices: +28.5%+5.8% Q4'25: +9.5% (vs Q4'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%-101.1% Q4'25: -115.6% (vs Q4'24)
-
EBIT margin Medical - Devices: +6.2%-90.4% Q4'25: -62.4% (vs Q4'24)
-
ROIC Medical - Devices: +3.3%-25.4% Q4'25: -19.7% (vs Q4'24)
-
Share dilution Medical - Devices: 0.0%+0.0% ★ Q4'25: +0.0% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-2.06× Q4'25: -2.92× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
81.11M
est: 82.94M (-2.2%)
|
107.30M
est: 140.35M (-23.5%)
|
140.90M
est: 254.51M (-44.6%)
|
207.98M
est: 229.92M (-9.5%)
|
299.11M
est: 261.90M (+14.2%)
|
233.27M
est: 358.85M (-35.0%)
|
427.30M
427.30M – 427.30M
+19.1% YoY
|
482.27M
482.27M – 482.27M
+12.9% YoY
|
457.60M
457.60M – 457.60M
-5.1% YoY
|
| EBITDA |
-873.32M
est: -74.98M (-1,064.8%)
|
-118.88M
est: -126.87M (+6.3%)
|
-117.73M
est: -230.06M (+48.8%)
|
-174.14M
est: -194.77M (+10.6%)
|
-253.30M
est: -221.86M (-14.2%)
|
-166.99M
est: -303.99M (+45.1%)
|
-361.97M
-361.97M – -361.97M
-19.1% YoY
|
-408.54M
-408.54M – -408.54M
-12.9% YoY
|
-387.64M
-387.64M – -387.64M
+5.1% YoY
|
| EBIT |
-880.05M
est: -78.33M (-1,023.5%)
|
-124.47M
est: -132.54M (+6.1%)
|
-126.12M
est: -240.34M (+47.5%)
|
-193.71M
est: -212.69M (+8.9%)
|
-267.79M
est: -242.28M (-10.5%)
|
-210.79M
est: -331.97M (+36.5%)
|
-395.28M
-395.28M – -395.28M
-19.1% YoY
|
-446.13M
-446.13M – -446.13M
-12.9% YoY
|
-423.31M
-423.31M – -423.31M
+5.1% YoY
|
| Net Income |
-877.05M
est: -1.16B (+24.6%)
|
-143.65M
est: -321.92M (+55.4%)
|
-123.16M
est: -164.97M (+25.3%)
|
-191.69M
est: -232.76M (+17.6%)
|
-237.03M
est: -183.19M (-29.4%)
|
-223.46M
est: -147.64M (-51.3%)
|
-65.25M
-65.25M – -65.25M
+55.8% YoY
|
-19.86M
-19.86M – -19.86M
+69.6% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
41.86M
est: 77.32M (-45.9%)
|
114.64M
est: 130.83M (-12.4%)
|
161.50M
est: 237.25M (-31.9%)
|
209.30M
est: 236.32M (-11.4%)
|
276.39M
est: 269.20M (+2.7%)
|
231.97M
est: 368.85M (-37.1%)
|
439.21M
439.21M – 439.21M
+19.1% YoY
|
495.71M
495.71M – 495.71M
+12.9% YoY
|
470.35M
470.35M – 470.35M
-5.1% YoY
|
| EPS |
-3.29
est: -4.25 (+22.6%)
|
-0.54
est: -1.18 (+54.1%)
|
-0.45
est: -0.60 (+25.4%)
|
-0.70
est: -0.85 (+17.7%)
|
-0.87
est: -0.67 (-29.9%)
|
-0.82
est: -0.54 (-51.9%)
|
-0.24
-0.24 – -0.24
+55.8% YoY
|
-0.07
-0.07 – -0.07
+69.6% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Liang | Chairman of the Board & GM | 4M | — |
| Lingyin Kong | Chief Technology Officer & Executive Director | 1M | male |
| Junchao Jiang | Executive Director | 1M | female |
| Ying Yang | Chief Quality Officer | 506.2K | female |
| Maoshe Rui | Chief Operating Officer | 353.6K | male |
| Ming Fai Chung | Joint Company Secretary | — | male |
| Wing Yi Wan | Joint Company Secretary | — | female |
| Lejun Yin | Chief Financial Officer & Joint Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2170.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
